Stifel analyst James Condulis lowered the price target on Cytokinetics (NASDAQ: CYTK) to $95.00 (from $96.00) while maintaining a Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE